Loading...
Abbisko Cayman Limited
2256.HK•HKSE
Healthcare
Biotechnology
HK$10.33
HK$-0.31(-2.91%)
Abbisko Cayman Limited (2256.HK) Financial Performance & Income Statement Overview
Review Abbisko Cayman Limited’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
2544.24%
↑ 2544.24%
Operating Income Growth
95.77%
↑ 95.77%
Net Income Growth
106.56%
↑ 106.56%
Operating Cash Flow Growth
97.09%
↑ 97.09%
Operating Margin
-4.28%
↓ 4.28%
Gross Margin
100.00%
↑ 100.00%
Net Profit Margin
5.62%
↑ 5.62%
ROE
1.38%
↑ 1.38%
ROIC
-1.10%
↓ 1.10%
Abbisko Cayman Limited (2256.HK) Income Statement & Financial Overview
Review Abbisko Cayman Limited's (2256.HK) income statement with detailed quarterly and annual figures.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $3.36M | $3.36M | $248.64M | $248.64M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $3.36M | $3.36M | $248.64M | $248.64M |
| Gross Profit Ratio | $1.00 | $1.00 | $1.00 | $1.00 |
| R&D Expenses | $118.15M | $118.15M | $107.54M | $107.54M |
| SG&A Expenses | $16.96M | $16.96M | $20.15M | $20.15M |
| Operating Expenses | $135.11M | $135.11M | $127.68M | $127.68M |
| Total Costs & Expenses | $135.11M | $135.11M | $127.68M | $127.68M |
| Interest Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $1.58M | $2.69M | $2.69M | $2.69M |
| EBITDA | -$130.17M | -$129.06M | $123.64M | $123.64M |
| EBITDA Ratio | -$38.75 | -$38.42 | $0.50 | $0.50 |
| Operating Income | -$131.75M | -$131.75M | $120.95M | $120.95M |
| Operating Income Ratio | -$39.22 | -$39.22 | $0.49 | $0.49 |
| Other Income/Expenses (Net) | $28.02M | $28.02M | $21.79M | $21.79M |
| Income Before Tax | -$103.73M | -$103.73M | $142.74M | $142.74M |
| Income Before Tax Ratio | -$30.88 | -$30.88 | $0.57 | $0.57 |
| Income Tax Expense | $14.48M | $14.48M | $39.35M | $39.35M |
| Net Income | -$89.24M | -$89.24M | $103.40M | $103.40M |
| Net Income Ratio | -$26.56 | -$26.56 | $0.42 | $0.42 |
| EPS | -$0.14 | -$0.14 | $0.16 | $0.16 |
| Diluted EPS | -$0.14 | -$0.14 | $0.16 | $0.16 |
| Weighted Avg Shares Outstanding | $628.77M | $628.77M | $646.22M | $646.22M |
| Weighted Avg Shares Outstanding (Diluted) | $628.77M | $628.77M | $651.92M | $651.92M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan